After imatinib: new hopes for chronic myeloid leukaemia.
作者信息
Bradbury Jane
出版信息
Drug Discov Today. 2005 Apr 15;10(8):536-7. doi: 10.1016/S1359-6446(05)03422-7.
Abstract
摘要
相似文献
1
After imatinib: new hopes for chronic myeloid leukaemia.
Drug Discov Today. 2005 Apr 15;10(8):536-7. doi: 10.1016/S1359-6446(05)03422-7.
2
Gleevec resistance: lessons for target-directed drug development.
Cell Cycle. 2003 May-Jun;2(3):190-1.
3
[New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia].
Zhonghua Zhong Liu Za Zhi. 2006 Aug;28(8):561-3.
4
New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865.
5
Is AMN-107 a step forward from imatinib in the treatment of chronic myeloid leukaemia?
Expert Opin Investig Drugs. 2005 Aug;14(8):1063-6. doi: 10.1517/13543784.14.8.1063.
6
[Molecular targeting therapy for chronic myeloid leukemia].
Rinsho Ketsueki. 2007 Jan;48(1):46-55.
7
Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
Mol Oncol. 2013 Dec;7(6):1103-15. doi: 10.1016/j.molonc.2013.08.006. Epub 2013 Aug 22.
8
Circumventing resistance to kinase-inhibitor therapy.
N Engl J Med. 2006 Jun 15;354(24):2594-6. doi: 10.1056/NEJMe068073.
9
Imatinib mesylate.
Am J Health Syst Pharm. 2001 Dec 1;58(23):2241-2. doi: 10.1093/ajhp/58.23.2241.
10
Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain.
Leuk Res. 2009 Sep;33(9):e157-8. doi: 10.1016/j.leukres.2009.03.040. Epub 2009 Apr 29.
Zotero 插件